EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

132P A phase I clinical trial of QLS31905 in advanced solid tumors

Y. Wang, J. Gong, Y. Sun, S. Yang, M. Zhang, J. Cui, J. Lv, H. Su, J. Wang, J. Lu, J. Shan, J. Zhang und 6 weitere

Immuno-Oncology and Technology · 2023-12 · 20 · 100604

DOI: 10.1016/j.iotech.2023.100604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno-Oncology and Technology, 2023-12. Verfasst von Y. Wang und 17 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

QLS31905 is a novel Claudin18.2/CD3 bi-specific antibody. This study aimed to evaluate its safety, tolerability, and antitumor activity in advanced solid tumors. This phase I trial (NCT05278832) recruited pts with advanced solid tumors who failed standard treatment, or were inapplicable to or had no standard treatment. The dose-escalation stage, adopting accelerated titration and interval 3+3 design, recruited pts regardless of Claudin 18.2 (CLDN18.2) expression. QLS31905 was administered in nine sequential single doses (0.5, 1.5, 5, 15, 45, 100, 200, 350, and 500 μg/kg qw or q2w) with/without priming dose. The dose-expansion stage recruited CLDN18.2-positive pts (expression ≥1% of tumor cells). The primary endpoint was dose limiting toxicities (DLT) and maximum tolerated dose (MTD) in dose-escalation stage, and was objective response rate (ORR) in dose-expansion stage. As of July 17, 2023, 52 pts were included. In dose-escalation stage, 22 pts were included from 0.5 to 350 μg/kg qw, and 500 μg/kg q2w cohort is ongoing. Two dose-expansion cohorts, 200 μg/kg qw or 350 μg/kg q2w, included 30 pts. Of 52 pts, 31 had gastric or gastro-esophageal junction cancer and 12 had pancreatic cancer (PC). DLT did not occur. MTD was not reached. Treatment-related adverse events (TRAEs) occurred in 51 pts (98.08%), of which 21 (40.38%) were ≥grade 3. Treatment-related serious adverse events (AEs) occurred in 10 (19.23%) pts. Two pts (3.85%) discontinued treatment due to AEs. The most common TRAE was fever (30, 57.69%), nausea (26, 50.00%), and decreased white blood cell count (18, 34.62%). Two pts had ≥grade 3 cytokine release syndrome, both in the 350 μg/kg qw cohort. Among pts in 200 μg/kg qw cohorts or above dose levels, ORR was 11.1% (3/27) and disease control rate (DCR) was 63.0% (17/27). Three pts with partial responses (2 in PC and 1 in gallbladder cancer) showed intermediate (≥40% of tumor cells) or high (≥70% of tumor cells) CLDN18.2 expression. Of 14 pts with SD (9 in gastric cancer, 4 in PC, and 1 in duodenal cancer), eight had target lesion reduction, among whom seven showed intermediate or high CLDN18.2 expression. QLS31905 showed safety, tolerability, and preliminary antitumor activity in advanced solid tumors.

Zitieren

APA

Wang, Y., Gong, J., Sun, Y., Yang, S., Zhang, M., Cui, J., Lv, J., Su, H., Wang, J., Lu, J., Shan, J., Zhang, J., Zhang, Y., Li, Y., Gu, L., Li, L., Kang, X., & Shen, L. (2023). 132P A phase I clinical trial of QLS31905 in advanced solid tumors. Immuno-Oncology and Technology, 20, 100604. https://doi.org/10.1016/j.iotech.2023.100604

Vancouver

Wang Y, Gong J, Sun Y, Yang S, Zhang M, Cui J, et al. 132P A phase I clinical trial of QLS31905 in advanced solid tumors. Immuno-Oncology and Technology. 2023;20:100604. doi:10.1016/j.iotech.2023.100604

BibTeX
@article{Wang2023,
  author = {Wang, Y. and Gong, J. and Sun, Y. and Yang, S. and Zhang, M. and Cui, J. and Lv, J. and Su, H. and Wang, J. and Lu, J. and Shan, J. and Zhang, J. and Zhang, Y. and Li, Y. and Gu, L. and Li, L. and Kang, X. and Shen, L.},
  title = {132P A phase I clinical trial of QLS31905 in advanced solid tumors},
  journal = {Immuno-Oncology and Technology},
  year = {2023},
  volume = {20},
  pages = {100604},
  doi = {10.1016/j.iotech.2023.100604}
}
Kostenlos starten →